Self-massage for pain

Intervention: This is a randomized pilot study with three comparative groups (two intervention conditions and one educational control group). All participants will receive an educational booklet about the sensations that precede pain and their relationship to Parkinson's disease. The control group will not receive additional treatment. The two intervention groups (global ALM and localized ALM) will participate in supervised sessions twice a week, on alternate days, lasting 60 minutes each, for 12 weeks, totaling 24 sessions. Treatment will be carried out in groups of up to five patients. The global ALM group (ALMG) will follow a protocol focused on the main muscles affected by Parkinson's disease, covering the body as a whole, regardless of the location of the pain reported by the patient, as described in the literature and based on the clinical experience of the researchers involved (N = 15). In turn, the localized ALM group (ALML) will perform the protocol specifically in the region of the referred pain, categorized into three areas: a) head, neck and upper limbs; b) hip and spine; c) lower limbs, ankles and feet. In total, 15 patients will undergo the ALML protocol, which may be distributed asymmetrically among these three subgroups, depending on the pain reported by each patient. The protocol for each of these regions will be structured considering the muscles most involved. Both protocols will have the same duration. The control group will receive a minimal intervention, consisting of a single educational session on Parkinson's disease and musculoskeletal pain. Primary outcome: The study is expected to be feasible, verified by the recruitment rate (number of participants included in the study), the retention rate (number of participants who completed the intervention), and the success of the implementation within the proposed environment.;The study is expected to be acceptable, verified by the acceptance rate (the proportion of eligible participants who consented to participate), protocol engagement (the proportion of completed sessions), participants' experience with implementation (the rate of agreeableness and satisfaction), and the overall satisfaction rating.;The study is expected to be adequate, verified by the identification of adverse events that are measured by the dropout rate due to problems related to the intervention, by the patient's perception of fit, and by the compatibility of the intervention in pain management.;The study is expected to adhere to the established protocol or the planned adaptations, verified through a description of the consistency of its application and any modifications made.;The study is expected to present the reality of the intervention implementation costs measured from a societal perspective over a six-month time horizon. The costs of implementing the intervention will be comprised of intervention costs, healthcare costs, patient and family costs, and costs associated with lost patient and family productivity. Secondary outcome: It is expected that self-myofascial release interventions will decrease pain intensity, as measured by the numerical pain scale. A two-point decrease on the pain scale is already considered a significant improvement in pain.;It is expected that self-myofascial release interventions will decrease the presence of kinesiophobia, as measured by the Tampa Scale for Kinesiophobia. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will decrease pain catastrophizing, as measured by the Pain Catastrophic Thinking Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve overall health performance, as measured by the Global Effect Perception Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will decrease fatigue, as verified by the Fatigue Severity Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will decrease symptoms of anxiety and depression, as verified by the Beck Inventory. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve trunk mobility, as verified by the Trunk Mobility Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve the level of activities in daily living, as verified by the Activities of Daily Living Questionnaire. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve patient-specific function, as verified by the Patient-Specific Functional Scale. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve the symptom-specific quality of life for Parkinson's disease, as measured by the PDQ-39. As this is a pilot study, the effect size will not be evaluated.;It is expected that self-myofascial release interventions will improve health-related quality of life, as measured by the EQ-5D-3L. As this is a pilot study, the effect size will not be evaluated.